Resultados: 4

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 1

    MMWR recomm. rep; 72 (34), 2023
    A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infecti...

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 2

    MMWR recomm. rep; 72 (34), 2023
    A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV))-associated lower respiratory tract infec...

    A British Society for haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies

    Br. j. haematol; 203 (4), 2023
    The objective of this guideline is to provide healthcare professionals with clear, up-to-date and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) and related thrombotic microangiopathies (TMAs), including complement-mediated haemolytic uraemic syndrome (CM HUS); these ar...

    Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

    Eur. respir. j; 57 (4), 2021
    Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of SARS-CoV-2 infection have a high mortality rate and frequently require noninvasive respiratory support or invasive ventilation. Optimising and standardising management through evidence-based guidelines may improve quality of ca...